Gene expression: protein interaction systems network modeling identifies transformation-associated molecules and pathways in ovarian cancer.
暂无分享,去创建一个
[1] Sven Diederichs,et al. The hallmarks of cancer , 2012, RNA biology.
[2] A. Berchuck,et al. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer , 2010, International journal of cancer.
[3] S. Bapat,et al. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. , 2009, Cancer research.
[4] A. Ghanate,et al. Snail and Slug Mediate Radioresistance and Chemoresistance by Antagonizing p53‐Mediated Apoptosis and Acquiring a Stem‐Like Phenotype in Ovarian Cancer Cells , 2009, Stem cells.
[5] C. Plass,et al. Copy number gain and oncogenic activity of YWHAZ/14‐3‐3ζ in head and neck squamous cell carcinoma , 2009, International journal of cancer.
[6] C Caldas,et al. Molecular classification of solid tumours: towards pathway-driven therapeutics , 2009, British Journal of Cancer.
[7] Kai Stoeber,et al. Cdc7 Kinase Is a Predictor of Survival and a Novel Therapeutic Target in Epithelial Ovarian Carcinoma , 2009, Clinical Cancer Research.
[8] Jingqin Luo,et al. Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome , 2009, Clinical Cancer Research.
[9] Takako Sasaki,et al. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker , 2009, International journal of cancer.
[10] S. Bapat,et al. CD133‐Expressing Stem Cells Associated with Ovarian Metastases Establish an Endothelial Hierarchy and Contribute to Tumor Vasculature , 2009, Stem cells.
[11] S. Gayther,et al. Ovarian Cancer: A Clinical Challenge That Needs Some Basic Answers , 2009, PLoS medicine.
[12] F. Pontén,et al. The Human Protein Atlas—a tool for pathology , 2008, The Journal of pathology.
[13] S. Leung,et al. Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.
[14] B. Karlan,et al. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target , 2008, Genes, chromosomes & cancer.
[15] J. Astola,et al. Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues , 2008, Genome Biology.
[16] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[17] M. Mansukhani,et al. Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: Potential role in progression , 2008, Genes, chromosomes & cancer.
[18] John L Hopper,et al. Multiple loci with different cancer specificities within the 8q24 gene desert. , 2008, Journal of the National Cancer Institute.
[19] Gang Meng,et al. Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. , 2008, Experimental and molecular pathology.
[20] Leslie Cope,et al. Convergence of Mutation and Epigenetic Alterations Identifies Common Genes in Cancer That Predict for Poor Prognosis , 2008, PLoS medicine.
[21] L. Myeroff,et al. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor β resistant cells , 2008, Genes, chromosomes & cancer.
[22] Carolyn J. Brown,et al. Epigenetics of cancer progression. , 2008, Pharmacogenomics.
[23] Y. Miyagi,et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. , 2007, Cancer research.
[24] M. Bieda,et al. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes , 2007, Proceedings of the National Academy of Sciences.
[25] Kelly M. McGarvey,et al. A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing , 2007, Nature Genetics.
[26] S. Bapat,et al. Nuclear–mitochondrial genomic profiling reveals a pattern of evolution in epithelial ovarian tumor stem cells , 2006, Oncogene.
[27] I. Shih,et al. Chromosomal losses of regions on 5q and lack of high‐level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma , 2006, Genes, chromosomes & cancer.
[28] David C. Corney,et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. , 2006, Cancer research.
[29] H. Sakurai,et al. The DNA-binding domain of yeast Hsf1 regulates both DNA-binding and transcriptional activities. , 2006, Biochemical and biophysical research communications.
[30] N. Kaminski,et al. Multiple imprinted and stemness genes provide a link between normal and tumor progenitor cells of the developing human kidney. , 2006, Cancer research.
[31] Jeffrey T. Chang,et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.
[32] V. Moreno,et al. Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy , 2005, Oncogene.
[33] M. McClelland,et al. “Promoter Array” Studies Identify Cohorts of Genes Directly Regulated by Methylation, Copy Number Change, or Transcription Factor Binding in Human Cancer Cells , 2005, Annals of the New York Academy of Sciences.
[34] S. Bapat,et al. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. , 2005, Cancer research.
[35] Shingo Matsumoto,et al. Loss of imprinting of PEG1/MEST in lung cancer cell lines. , 2004, Oncology reports.
[36] Chris Wiggins,et al. ARACNE: An Algorithm for the Reconstruction of Gene Regulatory Networks in a Mammalian Cellular Context , 2004, BMC Bioinformatics.
[37] M. Campbell,et al. PANTHER: a library of protein families and subfamilies indexed by function. , 2003, Genome research.
[38] U. Löhrs,et al. CAS (cellular apoptosis susceptibility) gene expression in ovarian carcinoma: Correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression. , 2002, American journal of clinical pathology.
[39] T. Goto,et al. Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer. , 2001, Human cell.
[40] M. Veigl,et al. Loss of DNA mismatch repair imparts defective cdc2 signaling and G(2) arrest responses without altering survival after ionizing radiation. , 2001, Cancer research.
[41] Jianmin Wu,et al. Integrated network analysis platform for protein-protein interactions , 2009, Nature Methods.
[42] J. Haerting,et al. Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.